First-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer

Implanted cell capsules are designed to release IL-2 over approximately one week, after which activity declines. Credit: Jeff Fitlow / Rice University

Continue Reading


News Source: medicalxpress.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *